Plain-English translation of NCT06699810 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a research study for people newly diagnosed with ketosis-prone diabetes—a rare condition where young, overweight adults suddenly develop severe diabetes with dangerously high acid levels in their blood. Researchers want to understand why about 70% of these patients can eventually stop taking , while others cannot. To do this, they'll have you wear a continuous glucose monitor (a small device that tracks your blood sugar throughout the day) from the time you leave the hospital until your doctor stops your .
Doctors don't fully understand why some people with this type of diabetes recover and can come off while others don't. By carefully tracking your blood sugar patterns over time, researchers hope to build a better mathematical model that explains these differences—which could one day help doctors predict who will recover and how long recovery might take.
You likely qualify if…
You likely don't qualify if…
When you leave the hospital after treatment for your diabetes crisis, a small continuous glucose monitor will be attached to your skin—similar to a patch—to track your blood sugar levels automatically throughout the day and night. Your doctor will adjust your doses based on the readings from this device. You'll wear the monitor until your doctor determines your blood sugar is stable enough to stop therapy, which typically takes several months. During this time, you'll have regular follow-up visits with your treatment team to monitor your progress.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Emory University
Enrollment target
~12 participants
Started
January 2025
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Priyathama Vellanki, MD, MS
Emory University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.